<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621227</url>
  </required_header>
  <id_info>
    <org_study_id>C3421007</org_study_id>
    <nct_id>NCT04621227</nct_id>
  </id_info>
  <brief_title>Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity</brief_title>
  <official_title>A PHASE 1, OPEN -LABEL, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF TWO STEADY STATE DOSE LEVELS OF PF-06882961 ON THE PHARMACOKINETICS OF SINGLE ORAL DOSES OF ROSUVASTATIN AND MIDAZOLAM IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OBESITY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On&#xD;
      Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With&#xD;
      Obesity&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to look at the effect of two doses of PF 06882961 (120 milligram (mg)&#xD;
      twice a day (BID) and 200 mg BID) on the levels of one dose of rosuvastatin 10 mg and one&#xD;
      dose of midazolam 2 mg, in otherwise healthy, adult participants with obesity. Total duration&#xD;
      of study from screening to the telephone visit will be approximately 17 weeks, of which up to&#xD;
      63 days will be inpatient. All subjects take (i) Rosuvastatin alone, Midazolam alone, PF&#xD;
      06882961 alone (120 mg BID), PF 06882961 (120 mg BID) + Rosuvastatin, PF 06882961 (120 mg&#xD;
      BID) + Midazolam, PF 06882961 (200 mg BID) alone, PF 06882961 (200 mg BID) + Rosuvastatin, PF&#xD;
      06882961 (200 mg BID)+ Midazolam in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Actual">May 13, 2021</completion_date>
  <primary_completion_date type="Actual">May 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of PF 06882961 on Rosuvastatin plasma pharmacokinetic parameter AUCinf (if data permits otherwise AUClast)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72 and 96 hours post dose on Day 1 at Periods 1, 4 and 7</time_frame>
    <description>Rosuvastatin plasma pharmacokinetic parameters: AUCinf (if data permits otherwise AUClast) in Periods 1, 4 and 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of PF 06882961 on midazolam pharmacokinetic parameter AUCinf (if data permits otherwise AUClast)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16 and 24 hours post dose on Day 1 at Periods 2, 5 and 8</time_frame>
    <description>Midazolam plasma pharmacokinetic parameters: AUCinf (if data permits otherwise AUClast) in Periods 2, 5 and 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-causality and Treatment-related Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From baseline to up to 35 days after last dose for a total of approximately 96 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality</measure>
    <time_frame>From baseline to up to 10 days after last dose for a total of approximately 71 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Vital Signs</measure>
    <time_frame>From baseline to up to 10 days after last dose for a total of approximately 71 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>From baseline to up to 10 days after last dose for a total of approximately 71 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG) Interval</measure>
    <time_frame>From baseline to up to 10 days after last dose for a total of approximately 71 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with categorical scores on the Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>From baseline to up to 10 days after last dose for a total of approximately 71 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with categorical scores on the Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>From baseline to up to 10 days after last dose for a total of approximately 71 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive the following treatments in this sequence : (i)Rosuvastatin alone (one dose of 10 mg), (ii) Midazolam alone (one dose of 2mg), (iii) PF 06882961 alone (120 mg twice daily), (iv) PF 06882961 (120 mg twice daily) + Rosuvastatin (one dose of 10mg), (v) PF 06882961 (120 mg) + Midazolam (one dose of 2 mg), (vi) PF 06882961 (200 mg) alone, (vii) PF 06882961 (200 mg) + Rosuvastatin (one dose of 10 mg), (viii) PF 06882961 (200 mg)+ Midazolam (one dose of 2 mg) in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>120 mg and 200 mg BID</description>
    <arm_group_label>Period 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>10 mg single dose</description>
    <arm_group_label>Period 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>2mg single dose</description>
    <arm_group_label>Period 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) â‰¥ 30.0 kg/m2 and not more than 45.4 kg/m2 at Screening.&#xD;
&#xD;
          -  Stable body weight, defined as &lt;5 kg change (per participant report) for 90 days&#xD;
             before Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known prior participation in a trial involving PF-06882961.&#xD;
&#xD;
          -  Known intolerance or hypersensitivity to GLP-1R agonists.&#xD;
&#xD;
          -  Known hypersensitivity to rosuvastatin or midazolam.&#xD;
&#xD;
          -  Diagnosis of type 1 or type 2 diabetes mellitus or secondary forms of diabetes at&#xD;
             screening. Note: prior diagnoses of gestational diabetes during pregnancy only are&#xD;
             eligible if they meet the other eligibility criteria&#xD;
&#xD;
          -  Any lifetime history of a suicide attempt.&#xD;
&#xD;
          -  Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more&#xD;
             within 60 days prior to dosing.&#xD;
&#xD;
          -  Participation in a formal weight reduction program (eg, Weight Watchers) within 90&#xD;
             days prior to Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3421007</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

